此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Outcome of Preserved Mitral Valve Apparatus During Mitral Valve Replacement (EarlyOutcome)

2022年6月23日 更新者:Hamdy Dosoky Ibraheem Elayouty、Suez Canal University

Outcome of Preservation of Mitral Valve Leaflets During Mitral Replacement

Are there differences in outcome of mitral valve replacement with preservation of mitral apparatus among rheumatic and/or ischemic mitral lesions?.

Mitral valve replacement with preservation of leaflets, and added coronary artery-bypass surgery, when indicated, is it a feasible and reproducible procedure?.

The study was designed to compare outcome after prosthetic mitral replacement with preservation of mitral apparatus for rheumatic valve disease with outcome of replacement for ischemic myocardium and mitral valve disease, The outcomes will be guided by clinical assessment. and echo-cardiograph.

研究概览

详细说明

Objectives: The aim is to compare outcome of modified preservation of mitral valve apparatus during prosthetic mitral replacement for rheumatic versus myocardial ischemia &mitral valve disease.

Methods ;This prospective cross-sectional comparative study will include 50 patients with isolated rheumatic mitral valve disease (group A) and 50 patients with mitral disease and myocardial ischemia (group B), surgery is expected to be performed between 2017 and 2020 at one center. All patients will have modified preservation of mitral apparatus during prosthetic mitral replacement. Additionally, group B patients will have bypass grafts to left anterior descending and/or posterior descending / right coronary artery. Data will be collected and analyzed.

The Institutional Review Board (IRB), Ethics Committee (EC)-approval and consent of each patient were obtained.

Criteria for inclusion of patients and exclusion of others were determined according to the guide lines.

Statistical analysis::

Qualitative variables and their association among both groups were studied by applying Chi-square test and Fisher Exact test. Quantitative variables among both groups were compared by applying independent samples t-test. P < 0.05 values mean statistically-significant results.

研究类型

介入性

注册 (实际的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Ismailia、埃及、+064
        • Suez Canal University
      • Ismailia、埃及、002-064
        • Suez Canal University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria::

Mitral stenosis (MS)

  • symptoms are severely limiting and cannot be managed with diuresis and heart rate control.

Mitral regurgitation(MR):

* acute severe MR require surgical correction for hemo-dynamics and relief of symptoms .

Chronic primary mitral regurgitation:

* rheumatic heart disease: replacement before irreversible changes occur can be curative.

Mixed Mitral Stenosis and Mitral Regurgitation:

  • If beta blockers and diuretics do not relieve symptoms, replacement should be performed only in patients who have severe limiting symptoms.
  • Myocardial ischemia associating or complicated with miral valve disease.

Exclusion criteria

  • Patients showing good response to medical therapy, and Cases complicated by:
  • ineffective endocarditis,
  • previous myocardial re-vascularization
  • ischemic ventricular septal defect,
  • left ventricular aneurysm,
  • Ruptured papillary muscles of mitral apparatus.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
假比较器:Group A
50 patients with isolated rheumatic mitral valve disease (group A)
St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
其他名称:
  • St.Jude bi leaflet prosthesis to replace diseased valve with preservation of leaflets with Myocardial re-vascularization
  • St.Jude prosthetic mitral replacement with preservation of valve apparatus and bypass grafts for associated coronary artery disease
其他:Group B
50 patients with mitral disease and myocardial ischemia (group B)
St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
其他名称:
  • St.Jude bi leaflet prosthesis to replace diseased valve with preservation of leaflets with Myocardial re-vascularization
  • St.Jude prosthetic mitral replacement with preservation of valve apparatus and bypass grafts for associated coronary artery disease

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Smoking index
大体时间:One week before surgery(or during first clinical visit) .
Number of Packs every day X number of years of smoking= Pack.year,
One week before surgery(or during first clinical visit) .
Age and gender for each participant
大体时间:One week before surgery .
Males above 40 years and Females above 45 years need pre-operative coronary angio-graph
One week before surgery .
For each participant: pathological:type of mitral valve lesion
大体时间:Seven days before surgery .
severe stenosis with mitral area < 1 cm square, severe regurgitation, or mixed lesions
Seven days before surgery .
For each participant: etiological :type of mitral valve lesion
大体时间:Seven days before surgery .
Rheumatic: distorted thickened leaflets,thickened fibrosed chordae
Seven days before surgery .
For each participant: etiological :type of mitral valve lesion
大体时间:Seven days before surgery- echo-cardiograph.
Rheumatic: distorted thickened leaflets,thickened fibrosed chordae or ischemic incompetence
Seven days before surgery- echo-cardiograph.
For each participant:, assessing sub-valvular apparatus
大体时间:One week before surgery. with Echo-cardiograph.
Thickened chordae, ruptured chordae, ischemia of papillary muscles or lateral ventricular wall.
One week before surgery. with Echo-cardiograph.
Abascal echo-cardiographic mitral valve score (Wilkins score)
大体时间:One week before surgery.with Echo-cardiograph
:if score is 8 or less it is good for balloon valvo-plasty, if > 8 surgery is recommended ( leaflet mobility, thickness and calcification. Fourthly, sub-valvular thickening., higher scores = more deterioration
One week before surgery.with Echo-cardiograph
left ventricular wall motion abnormality
大体时间:one week before surgery - with an echo-cardiograph
hypokinesia, Akinesia, Dyskinesia of certain segment(s)
one week before surgery - with an echo-cardiograph
Number of participants with Signs of left ventricular dysfunction
大体时间:seven days before surgery echo-cardiograph examination
low ejection fraction <52%, low stroke volume< 70 ml, low cardiac output <5 litres per minute
seven days before surgery echo-cardiograph examination
Number of participants with pre-operative coronary artery disease
大体时间:seven days before surgery, coronary angio-graph
Expected on clinical bases and .proved by Echo-cardiograph-findings
seven days before surgery, coronary angio-graph
Number of participants with pre-operative ischemic complications
大体时间:seven days before surgery echo-cardiograph examination
left ventricular thrombi, septal and left ventricular wall thickness in mm .
seven days before surgery echo-cardiograph examination
Assessment of any evolving new prosthetic valve dysfunction
大体时间:intra-operative trans-esophageal echo-cardiograph examination
Left atrioventricular outflow stenosis, prosthetic dysfunction due to preservation of valve apparatus
intra-operative trans-esophageal echo-cardiograph examination
Change in post-operative left ventricular functions
大体时间:5 days post-operatively and end of 6th and 12 months after surgery with Echo-Cardiograph
: Low Fractional Shortening < 28% , Ejection fraction < 40%,, increased left ventricular dimensions and volume
5 days post-operatively and end of 6th and 12 months after surgery with Echo-Cardiograph
Change of Prosthetic mitral valve functions
大体时间:Monthly through study completion up to 12 months after surgery..... with Echo-cardiograph
Development of para-valvular leak or central jet of regurgitation or stuck valve by a thrombus
Monthly through study completion up to 12 months after surgery..... with Echo-cardiograph

次要结果测量

结果测量
措施说明
大体时间
changes on Clinical examination
大体时间:Monthly up to 12 months after surgery)
local and general Examination,: a new murmur, evolving heart failure
Monthly up to 12 months after surgery)
Changes in Results of Prothrombin time, concentration and.International normalized ratio
大体时间:.Monthly through study completion up to 12 months.
Adjust dose of oral anticoagulant.( between double and half to three times the control) Dose usually ranges between 1 and 11 mg warfarin tablet daily.
.Monthly through study completion up to 12 months.
Mortality and Morbidity
大体时间:Monthly through study completion up to 12 months.
cause of mortality, type of morbidity: wound infection, hypertrophied scar, Kiloid Formation
Monthly through study completion up to 12 months.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Mohamed A. allaban, PhD、Suez Canal University, FOM- Research Ethics Committee

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年12月28日

初级完成 (实际的)

2020年1月1日

研究完成 (实际的)

2021年12月28日

研究注册日期

首次提交

2022年6月1日

首先提交符合 QC 标准的

2022年6月23日

首次发布 (实际的)

2022年6月30日

研究记录更新

最后更新发布 (实际的)

2022年6月30日

上次提交的符合 QC 标准的更新

2022年6月23日

最后验证

2022年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by H. D. Elayouty, H. S. Hassan and S.A. Elhafeez. The first draft of the manuscript was written by A. H.Elayouty and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

IPD 共享时间框架

Within 360 days

IPD 共享访问标准

h.dosoky@yahoo.com

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅